^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    botensilimab (AGEN1181)

    i
    Other names: AGEN1181, AGEN 1181, AGEN-1181
    Company:
    Agenus
    Drug class:
    CTLA4 antagonist
    Related drugs:
    7d
    A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma (clinicaltrials.gov)
    P2, N=220, Active, not recruiting, Agenus Inc. | Suspended --> Active, not recruiting
    Enrollment closed • Checkpoint inhibition • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    14d
    Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas (clinicaltrials.gov)
    P2, N=28, Recruiting, University of Colorado, Denver | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2024 --> Nov 2025
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Checkpoint block • Metastases
    |
    pegylated liposomal doxorubicin • balstilimab (AGEN2034) • botensilimab (AGEN1181) • zalifrelimab (UGN-301)
    28d
    Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer (clinicaltrials.gov)
    P2, N=0, Withdrawn, City of Hope Medical Center | N=84 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Metastases
    |
    Stivarga (regorafenib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    2ms
    KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer (clinicaltrials.gov)
    P1, N=50, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting | Phase classification: P2 --> P1
    Enrollment open • Phase classification • Metastases
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181) • Hiltonol (poly-ICLC)
    3ms
    Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients with Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy (clinicaltrials.gov)
    P1/2, N=28, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=63 --> 28
    Enrollment closed • Enrollment change • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    Stivarga (regorafenib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    3ms
    Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) (clinicaltrials.gov)
    P2, N=70, Not yet recruiting, Stingray Therapeutics
    New P2 trial • Combination therapy • Metastases
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    4ms
    Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, University of Southern California | Trial completion date: Jul 2027 --> Oct 2027 | Initiation date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jul 2026 --> Oct 2026
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    4ms
    C-800-01: Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer (clinicaltrials.gov)
    P1, N=550, Recruiting, Agenus Inc.
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase)
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    4ms
    Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer (clinicaltrials.gov)
    P2, N=84, Not yet recruiting, City of Hope Medical Center
    New P2 trial • Metastases
    |
    Stivarga (regorafenib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    4ms
    CIME: Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (clinicaltrials.gov)
    P3, N=124, Not yet recruiting, Centre Leon Berard | Initiation date: May 2024 --> Oct 2024
    Trial initiation date • Checkpoint inhibition • Tumor mutational burden • IO biomarker • Metastases
    |
    TMB (Tumor Mutational Burden) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    4ms
    FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1/2, N=86, Recruiting, City of Hope Medical Center | Trial completion date: Apr 2025 --> Oct 2025 | Trial primary completion date: Apr 2025 --> Oct 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    POLE (DNA Polymerase Epsilon)
    |
    Avastin (bevacizumab) • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181) • fluorouracil topical
    5ms
    Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy (clinicaltrials.gov)
    P1/2, N=63, Recruiting, City of Hope Medical Center | Trial completion date: Nov 2024 --> Oct 2025 | Trial primary completion date: Nov 2024 --> Oct 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    Stivarga (regorafenib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    5ms
    Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated BBB opening: A novel combinatorial immunotherapy regimen for gliomas. (PubMed, Neuro Oncol)
    Our findings demonstrate that FcE-aCTLA-4 promotes robust immunomodulatory and anti-tumor effects in murine gliomas and is significantly enhanced when combined with anti-PD-1, doxorubicin, and LIPU/MB. We are currently investigating this combinatory strategy in a clinical trial (clinicaltrials.gov NCT05864534).
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    doxorubicin hydrochloride • botensilimab (AGEN1181)
    6ms
    Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. (PubMed, Nat Med)
    The combination of BOT plus BAL demonstrated a manageable safety profile with no new immune-mediated safety signals and encouraging clinical activity with durable responses. ClinicalTrials.gov identifier: NCT03860272 .
    P1 data • Journal • Metastases
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    6ms
    KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase classification: P1 --> P2
    Phase classification • Metastases
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181) • Hiltonol (poly-ICLC)
    7ms
    Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008) (clinicaltrials.gov)
    P2, N=45, Recruiting, Immune Oncology Research Institute | Not yet recruiting --> Recruiting
    Enrollment open
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    7ms
    Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, University of Southern California | Trial completion date: Apr 2027 --> Jul 2027 | Initiation date: Apr 2024 --> Jul 2024 | Trial primary completion date: Apr 2026 --> Jul 2026
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    7ms
    KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    New P1 trial • Metastases
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181) • Hiltonol (poly-ICLC)
    8ms
    Study of AGEN1571 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Agenus Inc. | Recruiting --> Active, not recruiting | N=98 --> 22
    Enrollment closed • Enrollment change • Combination therapy • Metastases
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181) • AGEN1571
    8ms
    NEST-1: Combination Immunotherapy in Colorectal Cancer (clinicaltrials.gov)
    P2, N=36, Recruiting, Weill Medical College of Cornell University | Active, not recruiting --> Recruiting | N=12 --> 36 | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: May 2024 --> May 2025
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    9ms
    CIME: Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (clinicaltrials.gov)
    P3, N=124, Not yet recruiting, Centre Leon Berard
    New P3 trial
    |
    TMB (Tumor Mutational Burden) • LAG3 (Lymphocyte Activating 3) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2)
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    9ms
    Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer (clinicaltrials.gov)
    P1, N=67, Active, not recruiting, Agenus Inc. | Recruiting --> Active, not recruiting | N=200 --> 67
    Enrollment closed • Enrollment change • Combination therapy • Metastases
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF V600
    |
    botensilimab (AGEN1181) • AGEN2373
    9ms
    Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, University of Southern California
    New P1 trial • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    9ms
    Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases (clinicaltrials.gov)
    P2, N=24, Recruiting, Weill Medical College of Cornell University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD8 (cluster of differentiation 8)
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181) • dalutrafusp alfa (AGEN1423)
    9ms
    A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer (clinicaltrials.gov)
    P2, N=230, Active, not recruiting, Agenus Inc. | Trial primary completion date: Jan 2024 --> Feb 2025
    Trial primary completion date • Combination therapy • Metastases
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    9ms
    Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008) (clinicaltrials.gov)
    P2, N=45, Not yet recruiting, Immune Oncology Research Institute
    New P2 trial • Combination therapy
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    9ms
    Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases (clinicaltrials.gov)
    P2, N=24, Not yet recruiting, Weill Medical College of Cornell University
    New P2 trial
    |
    CD8 (cluster of differentiation 8)
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181) • dalutrafusp alfa (AGEN1423)
    10ms
    NEOASIS: Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations (clinicaltrials.gov)
    P2/3, N=92, Recruiting, The Netherlands Cancer Institute
    New P2/3 trial
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    10ms
    BBOpCo: Botensilimab and Balstilimab Optimization in Colorectal Cancer (clinicaltrials.gov)
    P2, N=15, Not yet recruiting, Nicholas DeVito, MD
    New P2 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    10ms
    A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer (clinicaltrials.gov)
    P2, N=38, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial • Combination therapy • Metastases
    |
    paclitaxel • Cyramza (ramucirumab) • balstilimab (AGEN2034) • botensilimab (AGEN1181) • AgenT-797
    11ms
    A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma (clinicaltrials.gov)
    P2, N=220, Suspended, Agenus Inc. | Trial completion date: Oct 2023 --> May 2028 | Recruiting --> Suspended | Trial primary completion date: Oct 2023 --> May 2028
    Trial completion date • Trial suspension • Trial primary completion date • Checkpoint inhibition • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    12ms
    Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=25, Recruiting, Northwestern University | Not yet recruiting --> Recruiting
    Enrollment open • Trial completion date • Trial primary completion date • Combination therapy
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    12ms
    Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas (clinicaltrials.gov)
    P2, N=28, Recruiting, University of Colorado, Denver | Trial completion date: Nov 2024 --> Nov 2025 | Trial primary completion date: Nov 2023 --> Nov 2024
    Trial completion date • Trial primary completion date • Combination therapy • Checkpoint inhibition • Checkpoint block • Metastases
    |
    doxorubicin hydrochloride • balstilimab (AGEN2034) • botensilimab (AGEN1181) • zalifrelimab (UGN-301)
    1year
    A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer (clinicaltrials.gov)
    P2, N=230, Active, not recruiting, Agenus Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    EGFR (Epidermal growth factor receptor) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Stivarga (regorafenib) • Lonsurf (trifluridine/tipiracil) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    1year
    NEST-1: Combination Immunotherapy in Colorectal Cancer (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Weill Medical College of Cornell University | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    1year
    Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Northwestern University | Phase classification: P=N/A --> P2
    Phase classification • Trial initiation date • Combination therapy
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    1year
    Next-generation CTLA-4 targeting molecules and combination therapy: promising strategies for improving cancer immunotherapy. (PubMed, Oncoimmunology)
    Next-generation anti-CTLA-4 antibodies, such as botensilimab, are showing promise in clinical trials. Combining botensilimab with RT and/or CD40 agonist may offer additional benefits for challenging tumor types.
    Journal • Combination therapy
    |
    CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • CD40 (CD40 Molecule)
    |
    botensilimab (AGEN1181)
    1year
    ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
    New P1 trial
    |
    balstilimab (AGEN2034) • botensilimab (AGEN1181)
    1year
    The Seven Trial: Exploiting the Unfolded Protein Response (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, HonorHealth Research Institute
    New P1 trial • Metastases
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5) • MUC16 (Mucin 16, Cell Surface Associated)
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel • balstilimab (AGEN2034) • botensilimab (AGEN1181) • celecoxib oral • chloroquine phosphate
    over1year
    ARCITECT: Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (clinicaltrials.gov)
    P2, N=120, Recruiting, Michael B. Atkins, MD | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    over1year
    Botensilimab, Balstilimab and Regorafenib for the Treatment of Patients With Microsatellite Stable Metastatic Colorectal Cancer Who Have Progressed on Prior Chemotherapy (clinicaltrials.gov)
    P1/2, N=63, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene)
    |
    BRAF wild-type
    |
    Stivarga (regorafenib) • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    over1year
    ARCITECT: Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical Trial (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, Michael B. Atkins, MD
    New P2 trial • Metastases
    |
    CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • balstilimab (AGEN2034) • botensilimab (AGEN1181)